CALTH. Inc Logo

CALTH. Inc

Develops AI-powered rapid diagnostic solutions for point-of-care and self-testing.

402420 | KO

Overview

Corporate Details

ISIN(s):
KR7402420004
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 창업로 54, 321호(시흥동, 기업성장센터), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CALTH Inc. is an in vitro diagnostics (IVD) company that develops and manufactures rapid diagnostic solutions. The company provides innovative healthcare services for point-of-care testing (POCT), self-testing, and precision medicine. Its core business is built upon two proprietary technologies: an "Engineered Nanotrap" system for high-sensitivity sample preprocessing and a deep learning-based algorithm for the rapid and accurate analysis of Lateral Flow Assay products. CALTH's mission is to improve quality of life by delivering fast, accurate, and low-cost diagnostic tools. The company operates in facilities certified with KGMP and ISO 13485:2016.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-11 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-11 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-11 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 82.8 KB
2025-08-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 88.1 KB
2025-08-06 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.2 KB
2025-07-29 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 35.1 KB
2025-07-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.2 KB
2025-07-17 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 54.6 KB
2025-06-19 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.8 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 16.4 KB
2025-03-21 00:00
Audit Report / Information
감사보고서제출
Korean 10.1 KB
2025-03-21 00:00
Annual Report
사업보고서 (2024.12)
Korean 971.9 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 103.1 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 7.5 KB
2025-02-06 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 5.8 KB

Automate Your Workflow. Get a real-time feed of all CALTH. Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CALTH. Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CALTH. Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.